Provectus Pharmaceuticals, Inc. and Its Subsidiaries programme Unregistered ... MarketWatch (press release) Its dermatological drug PH-10 also targets aberrant or diseased cells, with the current focus connected psoriasis and atopic dermatitis. Provectus has recently realized its Phase 2 trials of PV-10 as type A therapy for metastatic melanoma, and of PH-10 As a ... and more » Link To Article
No comments:
Post a Comment